BJCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BJCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Bioject Medical Technologies's 5-Year RORE % for the quarter that ended in Sep. 2011 was 0.00%.
The industry rank for Bioject Medical Technologies's 5-Year RORE % or its related term are showing as below:
The historical data trend for Bioject Medical Technologies's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioject Medical Technologies Annual Data | |||||||||||||||||||||
Trend | Mar01 | Mar02 | Dec03 | Dec04 | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | |||||||||||
5-Year RORE % | Get a 7-Day Free Trial | - | - | - | - | - |
Bioject Medical Technologies Quarterly Data | ||||||||||||||||||||
Dec06 | Mar07 | Jun07 | Sep07 | Dec07 | Mar08 | Jun08 | Sep08 | Dec08 | Mar09 | Jun09 | Sep09 | Dec09 | Mar10 | Jun10 | Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | |
5-Year RORE % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Bioject Medical Technologies's 5-Year RORE % falls into.
Bioject Medical Technologies's 5-Year RORE % for the quarter that ended in Sep. 2011 is calculated as:
5-Year RORE % | = | ( Most Recent EPS (Diluted) | - | First Period EPS (Diluted) ) | / | ( Cumulative EPS (Diluted) for 5-year | - | Cumulative Dividends per Share for 5-year ) |
= | ( 0.006 | - | -0.35 ) | / | ( -0.722 | - | 0 ) | |
= | 0.356 | / | -0.722 | |||||
= | -49.31 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2011 and 5-year before.
Bioject Medical Technologies (OTCPK:BJCT) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Thank you for viewing the detailed overview of Bioject Medical Technologies's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
James C Gale | director | 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019 |
Sanders Morris Harris Inc/fa | 10 percent owner, other: See General Remarks | 600 TRAVIS, SUITE 5900, HOUSTON TX 77002 |
David S Tierney | director | C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
Edward L Flynn | director, 10 percent owner | 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921 |
Life Sciences Opportunities Fund Ii Lp | 10 percent owner | 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
Lof Partners Llc | other: See general remarks | 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
Life Sciences Opportunities Fund Instittutional Ii Lp | 10 percent owner | 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
Randal D Chase | director | 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7 |
Brigid Makes | director | 20245 SW 95TH AVENUE, TUALATIN OR 97062 |
J Michael Redmond | officer: Sr. VP Bus Dev. | 10 CANTERBURY ROAD, WINDHAM NH 03087 |
Elan Corp Plc | 10 percent owner | TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000 |
Elan International Services Ltd | 10 percent owner | C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2 |
Elan Pharmaceutical Investments Ltd | 10 percent owner | 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999 |
John P Gandolfo | officer: CFO | 62 TERRACE ROAD, WAYNE NJ 07470 |
Grace K Fey | director | 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.